Literature DB >> 6604067

T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

C D Platsoucas, H J Hansen, J R Redman, S Berenson, B J Lee, B D Clarkson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6604067     DOI： 10.1007/bf00915352

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  45 in total

1.  Monocyte-mediated suppression of human B lymphocyte differentiation in vitro.

Authors:  W Knapp; G Baumgartner
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

2.  Infections complicating multiple myeloma and chronic lymphocytic leukemia.

Authors:  J J Twomey
Journal:  Arch Intern Med       Date:  1973-10

3.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

4.  Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; M Galinski; S Kempin; L Reich; B Clarkson; R A Good
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia.

Authors:  D Catovsky; F Lauria; E Matutes; R Foa; V Mantovani; S Tura; D A Galton
Journal:  Br J Haematol       Date:  1981-04       Impact factor: 6.998

6.  A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

7.  Idiotype-bearing and antigen-binding receptors produced by blood T lymphocytes in a case of human myeloma.

Authors:  J L Preud'homme; M Klein; S Labaume; M Seligmann
Journal:  Eur J Immunol       Date:  1977-12       Impact factor: 5.532

8.  Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis.

Authors:  W Pruzanski; M S Gidon; A Roy
Journal:  Clin Immunol Immunopathol       Date:  1980-10

9.  Further characterization of the human inducer T cell subset defined by monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

10.  Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma.

Authors:  V Caggiano; J Cuttner; A Solomon
Journal:  Blood       Date:  1967-09       Impact factor: 22.113
View more
  6 in total

1.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

2.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

3.  T-cell subsets in multiple myeloma. Impact of cytostatic treatment.

Authors:  A Wahlin; G Roos; J Holm
Journal:  Blut       Date:  1985-10

4.  Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.

Authors:  C Mathiot; J L Teillaud; M Elmalek; V Mosseri; L Euller-Ziegler; A Daragon; B Grosbois; J L Michaux; T Facon; J F Bernard
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

5.  Production of interleukin 2 in multiple myeloma.

Authors:  T Commes; B Klein; M Jourdan; R Bataille
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

6.  Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients.

Authors:  H M Serra; M J Mant; B A Ruether; J A Ledbetter; L M Pilarski
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.